Hendrix N, Oestreicher N, Lalla D, Dolan CM, et al. Residual Disease Burden After Neoadjuvant Therapy Among US Patients With High-Risk HER2-positive Early-Stage Breast Cancer: A Population Effectiveness Model. Clin Breast Cancer 2022 Sep 1. pii: S1526-8209(22)00189.
PMID: 36220724